Ultrahypofractionated radiotherapy yields non-inferior 10-year survival outcomes compared to conventional treatment in ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...

China: Researchers have found in a new study that three months of dual antiplatelet therapy in patients treated with Firehawk stents was found to be non-inferior to 12 months of therapy, ...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to ...

Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to ...

Ocular Therapeutix Inc. OCUL shares are down during Tuesday's premarket session following a significant announcement ...

Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...

Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...

Roche. Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease. 2026 Feb 16. Accessed 2026 Feb 16.

Vaxcyte Inc. (NASDAQ:PCVX) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, Vaxcyte Inc. (NASDAQ:PCVX) closed its public offering of the sale of 12.65 million ...